Cargando…

Monocytes Phenotype and Cytokine Production in Human Immunodeficiency Virus-1 Infected Patients Receiving a Modified Vaccinia Ankara-Based HIV-1 Vaccine: Relationship to CD300 Molecules Expression

A modified vaccinia Ankara-based HIV-1 vaccine clade B (MVA-B) has been tested for safety and immunogenicity in low-risk human immunodeficiency virus (HIV)-uninfected individuals and as a therapeutic vaccine in HIV-1-infected individuals on combined antiretroviral therapy (cART). As a therapeutic va...

Descripción completa

Detalles Bibliográficos
Autores principales:	Vitallé, Joana, Zenarruzabeitia, Olatz, Terrén, Iñigo, Plana, Montserrat, Guardo, Alberto C., Leal, Lorna, Peña, José, García, Felipe, Borrego, Francisco
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2017
Materias:	Immunology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520290/ https://www.ncbi.nlm.nih.gov/pubmed/28785262 http://dx.doi.org/10.3389/fimmu.2017.00836

Ejemplares similares

The Expression and Function of CD300 Molecules in the Main Players of Allergic Responses: Mast Cells, Basophils and Eosinophils
por: Vitallé, Joana, et al.
Publicado: (2020)

Increased expression levels of CD300c on basophils from allergic individuals()
por: Vitallé, Joana, et al.
Publicado: (2019)

NK Cell Metabolism and Tumor Microenvironment
por: Terrén, Iñigo, et al.
Publicado: (2019)

Altered Expression of CD300a Inhibitory Receptor on CD4+ T Cells From Human Immunodeficiency Virus-1-Infected Patients: Association With Disease Progression Markers
por: Vitallé, Joana, et al.
Publicado: (2018)

Polyfunctional HIV-1 specific response by CD8+ T lymphocytes expressing high levels of CD300a
por: Vitallé, Joana, et al.
Publicado: (2020)

Metabolic changes of Interleukin-12/15/18-stimulated human NK cells
por: Terrén, Iñigo, et al.
Publicado: (2021)

NK Cell-Based Immunotherapy in Renal Cell Carcinoma
por: Terrén, Iñigo, et al.
Publicado: (2020)

Identification and Functional Analysis of Human CD56(neg) NK Cells by Flow Cytometry
por: Orrantia, Ane, et al.
Publicado: (2020)

CD300a inhibits CD16-mediated NK cell effector functions in HIV-1-infected patients
por: Vitallé, Joana, et al.
Publicado: (2019)

Implication of Interleukin-12/15/18 and Ruxolitinib in the Phenotype, Proliferation, and Polyfunctionality of Human Cytokine-Preactivated Natural Killer Cells
por: Terrén, Iñigo, et al.
Publicado: (2018)

Human IgM(hi)CD300a(+) B Cells Are Circulating Marginal Zone Memory B Cells That Respond to Pneumococcal Polysaccharides and Their Frequency Is Decreased in People Living with HIV
por: Vitallé, Joana, et al.
Publicado: (2023)

The expression and function of human CD300 receptors on blood circulating mononuclear cells are distinct in neonates and adults
por: Zenarruzabeitia, Olatz, et al.
Publicado: (2016)

Human NK Cells in Autologous Hematopoietic Stem Cell Transplantation for Cancer Treatment
por: Orrantia, Ane, et al.
Publicado: (2021)

T Cell Activation, Highly Armed Cytotoxic Cells and a Shift in Monocytes CD300 Receptors Expression Is Characteristic of Patients With Severe COVID-19
por: Zenarruzabeitia, Olatz, et al.
Publicado: (2021)

Cytokine-Induced Memory-Like NK Cells: From the Basics to Clinical Applications
por: Terrén, Iñigo, et al.
Publicado: (2022)

CD300c is uniquely expressed on CD56(bright) Natural Killer Cells and differs from CD300a upon ligand recognition
por: Dimitrova, Milena, et al.
Publicado: (2016)

Modified Vaccinia virus Ankara but not vaccinia virus induces chemokine expression in cells of the monocyte/macrophage lineage
por: Lehmann, Michael H, et al.
Publicado: (2015)

Increased Frequency of CTLA-4 and PD-1 Expressing Regulatory T Cells and Basophils With an Activating Profile in Infants With Moderate-to-Severe Atopic Dermatitis Hypersensitized to Food Allergens
por: Bilbao, Agurtzane, et al.
Publicado: (2021)

A NKp80-Based Identification Strategy Reveals that CD56(neg) NK Cells Are Not Completely Dysfunctional in Health and Disease
por: Orrantia, Ane, et al.
Publicado: (2020)

Strong, but Age-Dependent, Protection Elicited by a Deoxyribonucleic Acid/Modified Vaccinia Ankara Simian Immunodeficiency Virus Vaccine
por: Chamcha, Venkateswarlu, et al.
Publicado: (2016)

IL-12/15/18-induced cell death and mitochondrial dynamics of human NK cells
por: Terrén, Iñigo, et al.
Publicado: (2023)

Purification of modified vaccinia virus Ankara from suspension cell culture
por: Jordan, Ingo, et al.
Publicado: (2015)

Elements in the Development of a Production Process for Modified Vaccinia Virus Ankara
por: Jordan, Ingo, et al.
Publicado: (2013)

Development of Modified Vaccinia Virus Ankara-Based Vaccines: Advantages and Applications
por: Orlova, Olga Vladimirovna, et al.
Publicado: (2022)

Modified vaccinia Ankara–Bavarian Nordic vaccine against mpox in children
por: Turtle, Lance, et al.
Publicado: (2023)

Shaping the tumor microenvironment with Modified Vaccinia Virus Ankara and TLR9 ligand
por: Préville, Xavier, et al.
Publicado: (2015)

Hazard Characterization of Modified Vaccinia Virus Ankara Vector: What Are the Knowledge Gaps?
por: Okeke, Malachy I., et al.
Publicado: (2017)

A vital gene for modified vaccinia virus Ankara replication in human cells
por: Sutter, Gerd
Publicado: (2020)

Evaluation of modified vaccinia virus Ankara based recombinant SARS vaccine in ferrets
por: Czub, Markus, et al.
Publicado: (2005)

Cell lines from the Egyptian fruit bat are permissive for modified vaccinia Ankara
por: Jordan, Ingo, et al.
Publicado: (2009)

Phase 1 Safety and Immunogenicity Evaluation of ADMVA, a Multigenic, Modified Vaccinia Ankara-HIV-1 B'/C Candidate Vaccine
por: Vasan, Sandhya, et al.
Publicado: (2010)

Intradermal but not intramuscular modified vaccinia Ankara immunizations protect against intravaginal tier2 simian-human immunodeficiency virus challenges in female macaques
por: Bollimpelli, Venkata S., et al.
Publicado: (2023)

Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial
por: Overton, Edgar Turner, et al.
Publicado: (2015)

Safety and Immunogenicity of Modified Vaccinia Ankara-Bavarian Nordic Smallpox Vaccine in Vaccinia-Naive and Experienced Human Immunodeficiency Virus-Infected Individuals: An Open-Label, Controlled Clinical Phase II Trial
Publicado: (2016)

Immune Requirements of Post-Exposure Immunization with Modified Vaccinia Ankara of Lethally Infected Mice
por: Lauterbach, Henning, et al.
Publicado: (2010)

Vaccination with recombinant modified vaccinia virus Ankara prevents the onset of intestinal allergy in mice
por: Bohnen, C, et al.
Publicado: (2013)

Non-plaque-forming virions of Modified Vaccinia virus Ankara express viral genes
por: Lülf, Anna-Theresa, et al.
Publicado: (2016)

Modified vaccinia virus Ankara as a vaccine against feline coronavirus: immunogenicity and efficacy
por: Hebben, Matthias, et al.
Publicado: (2004)

Heat-inactivated modified vaccinia virus Ankara boosts Th1 cellular and humoral immunity as a vaccine adjuvant
por: Yang, Ning, et al.
Publicado: (2022)

NK Cell Reconstitution After Autologous Hematopoietic Stem Cell Transplantation: Association Between NK Cell Maturation Stage and Outcome in Multiple Myeloma
por: Orrantia, Ane, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_fckimkjgl19acgk28cd8e14rrf